Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
Results from the survey will look to provide insights to aid in the development of possible resources that can support physicians in conducting early conversations about type 2 diabetes and optimize the limited time they have with patients by focusing on the elements that have the potential to make a difference. Proper, thoughtful and open communication between patients and physicians from the start may lead to better health outcomes overall.1,2
"Being diagnosed with type 2 diabetes can be a challenging and emotional period, which understandably, many people find overwhelming. Ensuring individuals have the support they need at this time as well as an understanding of the progressive nature of their condition and the importance of self-management — right from the start — is crucial to success in the long run. The early conversations people with type 2 diabetes have with their physicians are essential," said
The global survey will provide a snapshot of the current perceptions of both physicians and people living with type 2 diabetes about these important early conversations and will highlight challenges and potential areas for improvement. Resources based on the insights provided will be developed by the Boehringer Ingelheim and Lilly Diabetes alliance and will aim to support primary care physicians and people living with type 2 diabetes so they remain informed, motivated and confident in their efforts to actively manage their condition. Developing resources to help people with type 2 diabetes is becoming increasingly important, as the IDF estimates more than 592 million people worldwide will have diabetes by 2035.3 Initial survey findings are expected to be announced in 2014.
"The effective management of type 2 diabetes may involve changing a person's way of life, which requires a strong commitment by the patient," said
About the Survey
The survey is concentrated on the needs and realities of primary care. It utilizes a combination of both validated tools and new research approaches to investigate the early conversations in type 2 diabetes. It is expected to produce information on what patients take away from these conversations and how this is associated with patient well-being and other self-reported patient outcomes.
The survey has been developed with the help of a very impressive advisory board of professional experts, including: Mrs.
About Diabetes
Approximately 25.8 million Americans4 and an estimated 382 million people worldwide5 have type 1 or type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.4 Diabetes is a chronic disease that occurs when the body cannot produce enough insulin or cannot use insulin effectively.6 Diabetes was estimated to cost the U.S.
Boehringer Ingelheim and
In
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim,
As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about
For more information please visit www.us.boehringer-ingelheim.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions — from medicines to support programs and more — to make lives better.
For more information, visit www.lillydiabetes.com.
P-LLY
DI588813PR
Contact:
Executive Director, Public Relations
Email: kate.oconnor@boehringer-ingelheim.com
Phone: +1 (203) 791 6250
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: +1 (317) 651 9116
References
1. |
Aikens J, Bingham R, Piette J. Patient-provider communication and self-care behaviour among type 2 diabetes patients. Diabetes Educ 2005;31:681-90. |
2. |
Bundesmann R, |
3. |
|
4. |
|
5. |
|
6. |
|
7. |
|
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )
SOURCE
News Provided by Acquire Media